Replaces Prod. #: ALX-850-323/1
The ADMA (human) ELISA kit is a complete assay for the quantitative determination of ADMA concentration. This kit is to be used with serum, citrate- and EDTA-plasma from human origin. The ADMA (human) ELISA has no cross-reactivity with SDMA, NMMA or L-arginine.
Product Details
| Sensitivity: | 0.05μmol/l (expected value: 0.45µmol/l ± 0.19µmol/l) |
| |
| Assay Time: | 15 to 20 hours + 1 hour |
| |
| Applications: | ELISA
|
| |
| Application Notes: | For the quantitative determination of asymmetrical dimethylarginine (ADMA) in human serum, citrate- and EDTA-plasma. Does not cross-react with SDMA, NMMA or L-arginine. |
| |
| Wavelength: | 450 nm |
| |
| Species reactivity: | Human
|
| |
| Quantity: | 96 wells (~80 tests). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | +4°C |
| |
| Scientific Background: | Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis. NO is one of the major endothelium-derived vasoactive mediators and is involved in the modulation of blood flow and blood pressure. Even small changes of ADMA concentration alter vascular NO production, vascular tone, and systemic vascular resistence. Elevated ADMA concentrations are found in patients with diabetes mellitus, hypercholeste-rolemia, hypertension, pulmonary hypertension, peripheral arterial disease, chronic renal failure, preeclampsia or erectile dysfunction. ADMA is therefore a cardiovascular risk factor. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
| Compatibility: | This product is compatible with the Absorbance 96 Plate Reader.
 |
| |
Product Literature References
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers: A. Gessner, et al.; Cardiovasc. Diabetol.
21, 4 (2022),
Abstract;
Effect of omega-3 fatty acids supplementation combined with lifestyle intervention on adipokines and biomarkers of endothelial dysfunction in obese adolescents with hypertriglyceridemia: F. Huang, et al.; J. Nutr. Biochem.
64, 162 (2019),
Application(s): Human blood serum,
Abstract;
Impact of arsenic exposure on clinical biomarkers indicative of cardiovascular disease risk in Mexican women: Á.C. Ochoa-Martínez, et al.; Ecotoxicol. Environ. Saf.
169, 678 (2019),
Application(s): ELISA of human serum,
Abstract;
Plasmatic Concentrations of ADMA and Homocystein in Llama (Lama glama) and Regulation of Arginase Type II: An Animal Resistent to the Development of Pulmonary Hypertension Induced by Hypoxia: V. López, et al.; Front. Physiol.
9, 606 (2018),
Application(s): Plasma from newborn sheep and llama,
Abstract;
Full Text
Serum Concentrations of New Predictive Cardiovascular Disease Biomarkers in Mexican Women Exposed to Lead: Á.C. Ochoa-Martínez, et al.; Arch. Environ. Contam. Toxicol.
74, 248 (2018),
Application(s): ELISA of human serum,
Abstract;
Adipokines, asymmetrical dimethylarginine, and pulmonary function in adolescents with asthma and obesity: F. Huang, et al.; J. Asthma
54, 153 (2017),
Application(s): Human serum,
Abstract;
Asymmetric dimethylarginine and augmentation index in newly diagnosed patients with hypertension: M. Cakar, et al.; Angiology
66, 43 (2015),
Application(s): ELISA - Human Serum,
Abstract;
Nitric Oxide and Carbon Monoxide Production and Metabolism in Preeclampsia: R.M. Ehsanipoor, et al.; Reprod Sci.
20, 542 (2013),
Application(s): Human plasma,
Abstract;
Full Text
Effects of 7 days of arginine-alpha-ketoglutarate supplementation on blood flow, plasma L-arginine, nitric oxide metabolites, and asymmetric dimethyl arginine after resistance exercise: D.S. Willoughby, et al.; Int. J. Sport Nutr. Exerc. Metab.
21, 291 (2011),
Abstract;
Full Text
Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature: M. Potenza, et al.; Am. J. Physiol. Endocrinol. Metab.
297, E685 (2009),
Abstract;
Full Text
Related Products
